Headquartered in Emeryville, CA Fiscal year ends September NASDAQ: MGX metagenomi.co
Metagenomi Therapeutics, Inc. is an in vivo genome editing company that leverages its proprietary technologies to develop curative genetic medicines. Founded on the science of metagenomics — the study of genetic materials recovered from the natural environment — the company has discovered and developed a suite of novel CRISPR gene-editing tools designed to correct genetic mutations anywhere in the human genome. Its lead wholly-owned program, MGX-001, targets hemophilia A and is designed to provide a one-time curative treatment through targeted genome editing and durable gene expression, potentially enabling life-long protection from bleeding events and joint damage in adults and children. The company is also pursuing additional indications leveraging its site-specific genome integration system and has partnered assets targeting cardiometabolic diseases. Metagenomi is a pre-revenue, clinical-stage biotechnology company traded on Nasdaq. Updated
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Metagenomi Therapeutics, Inc. is an in vivo genome editing company that leverages its proprietary technologies to develop curative genetic medicines.
The Wall Street consensus 12-month price target for MGX is $7.00.
